Abstract 356: Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers.
Argun Akçakanat, Ecaterina E. Dumbrava, Kurt W. Evans, Ran Zhang et autres
us (code pays fourni par la source)
0 citations
Cancer Research